Prevail Therapeutics (PRVL) Stock Price, News & Analysis

Company Overview

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Key Stats

• Today's Range: $23.00 to $23.00
• 50-Day Range: $22.91 to $23.20
• 52-Week Range: $9.02 to $23.35
• Volume: N/A
• Average Volume: 955,800 shs
• Market Capitalization: $787.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRVL Stock Analysis - Frequently Asked Questions

How were Prevail Therapeutics' earnings last quarter?

Prevail Therapeutics Inc. (NASDAQ:PRVL) released its earnings results on Friday, November, 13th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.64) by $0.09.

When did Prevail Therapeutics IPO?

Prevail Therapeutics (PRVL) raised $126 million in an initial public offering on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of Prevail Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Prevail Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Alector (ALEC), Advanced Micro Devices (AMD), Atreca (BCEL) and Homology Medicines (FIXX).

Company Calendar

• Last Earnings: 11/13/2020
• Today: 6/10/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PRVL
• CIK: N/A
• Web: www.prevailtherapeutics.com
• Phone: 917-336-9310
• Fax: N/A
• Employees: 66
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$63.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -55.57%
• Return on Assets: -48.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.56
• Quick Ratio: 7.56

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.85 per share
• Price / Book: 4.74

Miscellaneous

• Outstanding Shares: 34,246,000
• Free Float: N/A
• Market Cap: $787.66 million
• Optionable: Not Optionable
• Beta: 1.59